ClinicalTrials.gg
Active, not recruitingNCT02972840Updated Oct 8, 2026

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

A Phase 3 interventional study of Acalabrutinib and Bendamustine in Lymphoma, Mantle Cell, sponsored by Acerta Pharma BV. Active, not recruiting at 228 sites in 27 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
635
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell — 5 open to participants now, 20 under way, 1 of them phase 3. acalabrutinib · Lymphoma, Mantle-Cell.

Enrollment
Largest of 26
635 · median 49
Started
2017
the only one that year
Phase 3
2 of 26
none open now
Primary completion
2027-02
later than 8 of 19 live
Registered
5th of 26
by date
Lead sponsor
5 of 26
Acerta Pharma BV

Among the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, this one has the largest enrollment, is the only one that started in 2017, is one of 2 in phase 3, reaches primary completion later than 8 of the 19 other live ones, and was the 5th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

5 of the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

Read the detailed description

To evaluate the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per the Lugano Classification for Non-Hodgkin Lymphoma (NHL) in subjects with previously untreated mantle cell lymphoma (MCL).

03

Conditions studied

  • Lymphoma, Mantle Cell

Keywords

  • Bruton tyrosine kinase inhibitor
  • Acalabrutinib
  • Mantle Cell Lymphoma
  • ACE-LY-308
  • Treatment naive
  • non-Hodgkins Lymphoma
  • Bendomustine
  • Rituximab
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, ≥ 65 years of age.
  • confirmed MCL, with documentation of a chromosome translocation t(11;14)(q13;q32) and/or overexpression of cyclin D1 in association with other relevant markers (eg, CD5, CD19, CD20, PAX5) .
  • MCL requiring treatment and for which no prior systemic anticancer therapies have been received.
  • (ECOG) performance status of ≤ 2.
  • Agreement to use highly effective forms of during the study and 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longest .

Exclusion criteria

Exclusion Criteria:

  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the Functional Classification, or interval (QTc) > 480 msec (calculated using Friderica's formula: QT/RR0.33) at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  • Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti infective treatment within 2 weeks before first dose of study drug.
  • Concurrent participation in another therapeutic clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
635 participants (actual)

Study arms

  • Experimental
    Acalabrutinib in combination with bendamustine and rituximab

    Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.

    Drug: Acalabrutinib · Drug: Bendamustine · Drug: Rituximab

  • Placebo comparator
    Placebo in combination with bendamustine and rituximab

    Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.

    Drug: Bendamustine · Drug: Rituximab · Drug: Placebo

Interventions

  • Administered orally (PO)

    Also known as: ACP-196, Calquence

  • Administered intravenously (IV)

    Also known as: Treanda, Bendeka

  • Administered intravenously (IV)

    Also known as: Rituxan, Rituxan Hycela

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2

    Defined as the time from the date of randomization until disease progression (assessed by the IRC per the Lugano Classification for NHL) or death from any cause, whichever occurs first.

    Time frame: Up to 6 years

Secondary outcomes

  1. Investigator-assessed progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2

    Defined as the time from the date of randomization until disease progression (assessed by the investigator per the Lugano Classification for NHL) or death from any cause, whichever occurs first.

    Time frame: Up to 6 years

  2. Investigator-assessed overall response rate per the Lugano Classification for NHL in Arm 1 compared to Arm 2

    Defined as the proportion of subjects who achieve either partial response (PR) or complete response (CR) as best overall response according to the Lugano Classification for NHL as assessed by investigator.

    Time frame: Up to 6 years

  3. IRC-assessed overall response rate per the Lugano Classification for NHL in Arm 1 compared to Arm 2

    Defined as the proportion of subjects who achieve either PR or CR as best overall response according to the Lugano Classification for NHL as assessed by IRC.

    Time frame: Up to 6 years

  4. Overall survival in Arm 1 compared to Arm 2

    Defined as the time from randomization until the date of death from any cause.

    Time frame: Up to 6 years

  5. IRC-assessed duration of response per the Lugano Classification for NHL in Arm 1 compared to Arm 2

    Defined as the time from the first documentation of CR or PR to disease progression per the Lugano Classification for NHL or death from any cause, whichever occurs first.

    Time frame: Up to 6 years

  6. IRC assessed time to response per the Lugano Classification for NHL in Arm 1 compared to Arm 2

    Defined as the time from randomization to the first CR or PR per the Lugano Classification for NHL.

    Time frame: Up to 6 years

07

Study locations

228 sites
  • Research Site
    Tucson, Arizona 85719, United States
  • Research Site
    Downey, California 90241, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Tallahassee, Florida 32308-5304, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Rochester, Minnesota 55905-0001, United States
  • Research Site
    Kansas City, Missouri 64132, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    Morristown, New Jersey 07960, United States
  • Research Site
    Hawthorne, New York 10532, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    San Antonio, Texas 78217, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Fort Belvoir, Virginia 22060, United States
  • Research Site
    Seattle, Washington 98108, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Seattle, Washington 98122, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Buenos Aires, C1114AAP, Argentina
  • Research Site
    Buenos Aires, C1426ANZ, Argentina
  • Research Site
    Buenos Aires, C1430EGF, Argentina
  • Research Site
    Buenos Aires, C1431FWO, Argentina
  • Research Site
    Caba, C1118AAT, Argentina
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    Bedford Park, 5042, Australia
  • Research Site
    Concord, 2139, Australia
  • Research Site
    Frankston, 3199, Australia
  • Research Site
    Gosford, 2250, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Herston, QLD, 4029, Australia
  • Research Site
    Kogarah, NSW 2217, Australia
  • Research Site
    Murdoch, 6150, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Newcastle, 2298, Australia
  • Research Site
    Southport, 4215, Australia
  • Research Site
    Sydney, NSW 2145, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Antwerp, 2060, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Roeselare, 8900, Belgium
  • Research Site
    Sint-Niklaas, 9100, Belgium
  • Research Site
    Bela Vista, 01321-001, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Porto Alegre, RS 90610-000, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Salvador, 41253-190, Brazil
  • Research Site
    São Paulo, 01232-010, Brazil
  • Research Site
    São Paulo, 05652-9000, Brazil
  • Research Site
    São Paulo, 1236030, Brazil
  • Research Site
    São Paulo, 5403, Brazil
  • Research Site
    So Paulo, 08270-070, Brazil
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9,, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Edmonton, T6G 1Z2, Canada
  • Research Site
    Greenfield Park, J4V 2H1, Canada
  • Research Site
    Halifax, NS B3H 2Y9, Canada
  • Research Site
    Beijing, 100036, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chongqing, 400037, China
  • Research Site
    Dalian, 116023, China
  • Research Site
    Gongshu District, 310022, China
  • Research Site
    Haidian District, 100191, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanchang, 330029, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Qingdao, 266100, China
  • Research Site
    Shanghai, China
  • Research Site
    Shenyang, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Tianjian, 300020, China
  • Research Site
    Tianjin, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Wuhou District, 610041, China
  • Research Site
    Xicheng District, 100050, China
  • Research Site
    Xuhui District, 200032, China
  • Research Site
    Xuzhou, 221000, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Zhengzhou, 450008, China

Showing the first 100 of 228 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, Paludo J, Chu MP, Kryachok I, Fogliatto L, Cheah CY, Morawska M, Sancho JM, Li Y, Patti C, Forsyth C, Zhang J, Lesley R, Ramadan S, Rule S, Dreyling M; ECHO investigators; ECHO Investigators. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10;43(20):2276-2284. doi: 10.1200/JCO-25-00690. Epub 2025 May 1. PubMed 40311141 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2017 (actual). Primary completion is estimated for Feb 2027, 118 months after the start.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's planned 118 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2016
First posted
Nov 25, 2016
StartActual
Apr 5, 2017
Primary completionEst.
Feb 15, 2027
CompletionEst.
Feb 15, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02972840
Lead sponsor
Acerta Pharma BV
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Nov 25, 2016
Start date
Apr 5, 2017
Primary completion
Feb 15, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion